CLINICAL & PIPELINE·PHASE III READOUT
Oral PCSK9 Inhibitor Meets Primary Endpoint in 14,000-Patient Cardiovascular Outcomes Trial
Topline data positions the candidate as a potential first-in-class oral therapy; regulatory filing guided for H2 2026.
90-Day Activity